Efficacy and safety of liraglutide in type 2 diabetes mellitus patients complicated with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials.

Wang L, Xin Q, Wang Y, Chen Z, Yuan R, Miao Y, Zhang G, Cong W

Pharmacological research9 Jul 2021Cited by 13 (Europe PMC)

PMID34252552DOI10.1016/j.phrs.2021.105765PepBankPUB-34252552

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and coronary artery disease, meta-analysis of randomized trials found that liraglutide reduced HbA1c (WMD -0.67).
In plain wordsIn adults with type 2 diabetes and heart artery disease, pooled trials showed liraglutide lowered HbA1c.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
WMD
−0.67
HbA1c
Source sentences
Summary
reduced hemoglobin A1c (HbA1c) (WMD = -0.67; 95% CI[-0.94 to -0.39]
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 RCTs including 1557 patients with T2DM complicated with CAD were included.
Report a problemFND-3425255201
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and coronary artery disease, meta-analysis of randomized trials found that liraglutide reduced fasting plasma glucose (WMD -0.80).
In plain wordsIn adults with type 2 diabetes and heart artery disease, pooled trials showed liraglutide lowered fasting blood sugar.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
WMD
−0.8
fasting plasma glucose
Source sentences
Summary
fasting plasma glucose (FPG) (WMD = -0.80; 95% CI[-1.06 to -0.54]
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 RCTs including 1557 patients with T2DM complicated with CAD were included.
Report a problemFND-3425255202
03HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and coronary artery disease, meta-analysis of randomized trials found that liraglutide reduced 2 h plasma glucose (WMD -1.64).
In plain wordsIn adults with type 2 diabetes and heart artery disease, pooled trials showed liraglutide lowered blood sugar two hours after a meal.
Peptide
Liraglutide
Outcome
Decrease2-hour plasma glucose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
WMD
−1.64
2 h plasma glucose
Source sentences
Summary
2 h plasma glucose (2hPG) (WMD = -1.64; 95% CI[-2.12 to -1.16]
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 RCTs including 1557 patients with T2DM complicated with CAD were included.
Report a problemFND-3425255203
04HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and coronary artery disease, meta-analysis of randomized trials found that liraglutide improved left ventricular ejection fraction (WMD 4.79).
In plain wordsIn adults with type 2 diabetes and heart artery disease, pooled trials showed liraglutide improved the heart's pumping fraction.
Peptide
Liraglutide
Outcome
IncreaseLeft ventricular ejection fraction
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
WMD
4.79
LVEF
Source sentences
Summary
improved left ventricular ejection fraction(LVEF) (WMD = 4.79; 95% CI[4.08-5.51]
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 RCTs including 1557 patients with T2DM complicated with CAD were included.
Report a problemFND-3425255204
05HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and coronary artery disease, meta-analysis of randomized trials found that liraglutide reduced left ventricular end-diastolic diameter (WMD -5.70).
In plain wordsIn adults with type 2 diabetes and heart artery disease, pooled trials showed liraglutide reduced the end-diastolic width of the left heart chamber.
Peptide
Liraglutide
Outcome
DecreaseLeft ventricular end-diastolic diameter
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
WMD
−5.7
LVEDD
Source sentences
Summary
left ventricular end-diastolic diameter (LVEDD) (WMD = -5.70; 95% CI[-6.67 to -4.72]
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 RCTs including 1557 patients with T2DM complicated with CAD were included.
Report a problemFND-3425255205
06HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and coronary artery disease, meta-analysis of randomized trials found that liraglutide improved the E/A ratio (WMD 0.13).
In plain wordsIn adults with type 2 diabetes and heart artery disease, pooled trials showed liraglutide improved a measure of heart filling.
Peptide
Liraglutide
Outcome
IncreaseE/A ratio
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
WMD
0.13
E/A
Source sentences
Summary
E/A (WMD = 0.13; 95% CI[0.11-0.14]
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 RCTs including 1557 patients with T2DM complicated with CAD were included.
Report a problemFND-3425255206
07HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and coronary artery disease, meta-analysis of randomized trials found that liraglutide improved left ventricular posterior wall thickness (WMD -1.86).
In plain wordsIn adults with type 2 diabetes and heart artery disease, pooled trials showed liraglutide reduced the thickness of the left heart wall.
Peptide
Liraglutide
Outcome
DecreaseLeft ventricular posterior wall thickness
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
WMD
−1.86
LVPWT
Source sentences
Summary
left ventricular posterior wall thickness (LVPWT) (WMD = -1.86; 95% CI[-2.16 to -1.55]
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 RCTs including 1557 patients with T2DM complicated with CAD were included.
Report a problemFND-3425255207
08HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and coronary artery disease, meta-analysis of randomized trials found that liraglutide reduced total cholesterol (WMD -0.48).
In plain wordsIn adults with type 2 diabetes and heart artery disease, pooled trials showed liraglutide lowered total cholesterol.
Peptide
Liraglutide
Outcome
DecreaseTotal cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated
Measurements
WMD
−0.48
total cholesterol
Source sentences
Summary
reduced total cholesterol (TC) (WMD = -0.48; 95% CI[-0.56 to -0.39]
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 RCTs including 1557 patients with T2DM complicated with CAD were included.
Report a problemFND-3425255208
09HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and coronary artery disease, meta-analysis of randomized trials found that liraglutide reduced triglycerides (WMD -0.42).
In plain wordsIn adults with type 2 diabetes and heart artery disease, pooled trials showed liraglutide lowered triglycerides.
Peptide
Liraglutide
Outcome
DecreaseTriglycerides
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated
Measurements
WMD
−0.42
triglycerides
Source sentences
Summary
triglycerides (TG) (WMD = -0.42; 95% CI[-0.59 to -0.26]
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 RCTs including 1557 patients with T2DM complicated with CAD were included.
Report a problemFND-3425255209
10HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and coronary artery disease, meta-analysis of randomized trials found that liraglutide reduced LDL cholesterol (WMD -0.41).
In plain wordsIn adults with type 2 diabetes and heart artery disease, pooled trials showed liraglutide lowered LDL cholesterol.
Peptide
Liraglutide
Outcome
DecreaseLDL cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated
Measurements
WMD
−0.41
LDL-C
Source sentences
Summary
low-density lipoprotein cholesterol (LDL-C) (WMD = -0.41; 95% CI[-0.55 to -0.26]
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 RCTs including 1557 patients with T2DM complicated with CAD were included.
Report a problemFND-3425255210
11HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and coronary artery disease, meta-analysis of randomized trials found that liraglutide increased HDL cholesterol.
In plain wordsIn adults with type 2 diabetes and heart artery disease, pooled trials showed liraglutide raised HDL cholesterol.
Peptide
Liraglutide
Outcome
IncreaseHDL cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
increased high-density lipoprotein cholesterol (HDL-C) (WMD = -0.19; 95% CI[0.13-0.24]
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 RCTs including 1557 patients with T2DM complicated with CAD were included.
Report a problemFND-3425255211
12HumanSystematic reviewSafety outcome
In adults with type 2 diabetes and coronary artery disease, meta-analysis of randomized trials found that liraglutide did not increase hypoglycemia (OR 0.75).
In plain wordsIn adults with type 2 diabetes and heart artery disease, pooled trials found liraglutide did not raise the rate of low blood sugar.
Peptide
Liraglutide
Outcome
No significant changeHypoglycaemia incidence
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated
Measurements
OR
0.75
hypoglycemia
Source sentences
Summary
liraglutide did not increase the incidence of hypoglycemia (OR = 0.75, 95% CI[0.32-1.77], P = 0.51)
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 RCTs including 1557 patients with T2DM complicated with CAD were included.
Report a problemFND-3425255212
13HumanSystematic reviewSafety outcome
In adults with type 2 diabetes and coronary artery disease, meta-analysis of randomized trials found that liraglutide did not increase gastrointestinal events (OR 1.15).
In plain wordsIn adults with type 2 diabetes and heart artery disease, pooled trials found liraglutide did not raise the rate of stomach and bowel problems.
Peptide
Liraglutide
Outcome
No significant changeGastrointestinal events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Measurements
OR
1.15
gastrointestinal events
Source sentences
Summary
gastrointestinal (OR = 1.15, 95% CI[0.72-1.85], P = 0.55)
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 RCTs including 1557 patients with T2DM complicated with CAD were included.
Report a problemFND-3425255213

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.